Stryker Corporation 10-Q Summary: Period Ended September 30, 2008
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2008, and the nine-month period ended on that date. Stryker Corporation is a leading medical technology company with operations in two primary segments: Orthopaedic Implants and MedSurg Equipment. The company reported as a large accelerated filer with 403.7 million shares of common stock outstanding as of the reporting date.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|
| Net Sales | $1,653.0 million | $5,000.0 million |
| Gross Profit | $1,111.3 million (67.2% margin) | $3,424.6 million (68.5% margin) |
| Operating Income | $364.1 million (22.0% margin) | $1,148.7 million (23.0% margin) |
| Net Earnings | $273.8 million | $870.1 million |
| Diluted EPS | $0.66 | $2.09 |
| Cash from Operations | $325.5 million | $756.6 million |
| Cash and Equivalents | $668.0 million (as of Sep 30, 2008) | |
| Marketable Securities | $1,539.5 million (current) + $154.3 million (non-current ARS) | |
| Debt (Current Maturities) | $21.2 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14% in the third quarter and 15% for the nine-month period compared to 2007. Growth was driven by increased unit volume and product mix, with favorable foreign currency impacts of 2% (Q3) and 4% (9 months).
- Profitability: Net earnings from continuing operations rose 20% in Q3 and 22% for the nine-month period. Operating margins improved slightly due to controlled discretionary spending, despite higher commodity and freight costs.
- Cost Structure: Cost of sales as a percentage of net sales increased to 32.8% in Q3 (from 31.4% in 2007) due to quality initiative costs and higher input prices. R&D expenses decreased as a percentage of sales (5.6% in Q3 vs. 6.7% in 2007) due to a normalization of spending levels.
- Capital Allocation: The company repurchased 9.1 million shares for $596.0 million in Q3, completing a $750 million program. No cash dividends were declared in 2008.
Guidance, Outlook, and Risks
Outlook: Management projects 2008 diluted net earnings per share to approximate $2.88, a 22% increase over 2007. The forecast includes a constant currency net sales increase of 11% to 12%. Management anticipates an unfavorable foreign currency impact of 4.5% to 5.5% in Q4 2008.
Investment Liquidity (ARS): The company holds $166.8 million in par value of Auction-Rate Securities (ARS) with a fair value of $152.1 million. Due to failed auctions since February 2008, these are classified as non-current assets. Management has not recorded an impairment charge, intending to hold until maturity or recovery. In October 2008, UBS offered to repurchase these securities at par value starting June 30, 2010.
Legal and Regulatory Contingencies:
- DOJ Subpoenas: Received subpoenas regarding false Institutional Review Board approvals, OP-1 sales under Humanitarian Device Exemption, and off-label promotion of Calstrux.
- FDA Warning Letters: Received letters in 2008 and 2007 regarding quality system compliance at facilities in Massachusetts, Ireland, and New Jersey.
- Non-Prosecution Agreement: Subject to an 18-month federal monitor regarding payments to orthopedic surgeons.
- Antitrust: DOJ closed its grand jury investigation into antitrust violations in the orthopaedic implants industry in 2008.
Investor Verification Checklist
- Verify the status of the UBS offer to repurchase Auction-Rate Securities (ARS) at par value and its potential impact on liquidity.
- Monitor the resolution of DOJ and HHS subpoenas regarding OP-1 and surgeon compensation practices.
- Track the impact of foreign currency exchange rates on Q4 2008 sales, as management forecasts a 4.5% to 5.5% negative impact.
- Review the progress of new product launches (FlexiCore, CerviCore, Sightline) which are critical to future growth targets.
- Confirm the effectiveness of cost containment measures given rising commodity and freight costs impacting gross margins.